Ra Medical Systems (RMED) Tops Q1 EPS by 46c, Revenues Beat

Ra Medical Systems (NYSE: RMED) reported Q1 EPS of ($2.48), $0.46 better than the analyst estimate of ($2.94). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $990 thousand.

Recent Operational Highlights

• Enrolled 20 subjects in the company’s atherectomy pivotal clinical study since mid-March for a total of 50 subjects enrolled to date
• Completed in-house real time aging tests that support shelf life of at least six months for next-generation DABRA catheters
• Continued dermatology segment revenue improvement as COVID-19 restrictions are lifted
• “I’m pleased by our recent progress, particularly with the increased enrollment in our atherectomy pivotal study. We have enrolled 20 subjects since mid-March bringing total enrollment to 50, reaching the halfway point in this 100-subject study,” said Will McGuire, Ra Medical Systems CEO. “We also recently generated six-month real time aging data with the next generation DABRA catheter. This important milestone gives me confidence we have strong data to support this catheter’s extended shelf life when we submit to the FDA for approval later this year.”

For earnings history and earnings-related data on Ra Medical Systems (RMED) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August